Literature DB >> 19095788

Proton MR spectroscopy improves discrimination between tumor and pseudotumoral lesion in solid brain masses.

C Majós1, C Aguilera, J Alonso, M Julià-Sapé, S Castañer, J J Sánchez, A Samitier, A León, A Rovira, C Arús.   

Abstract

BACKGROUND AND
PURPOSE: Differentiating between tumors and pseudotumoral lesions by conventional MR imaging may be a challenging question. This study aims to evaluate the potential usefulness and the added value that single-voxel proton MR spectroscopy could provide on this discrimination.
MATERIALS AND METHODS: A total of 84 solid brain lesions were retrospectively included in the study (68 glial tumors and 16 pseudotumoral lesions). Single-voxel spectra at TE 30 ms (short TE) and 136 ms (long TE) were available in all cases. Two groups were defined: "training-set" (56 cases) and "test-set" (28 cases). Tumors and pseudotumors were compared in the training-set with the Mann-Whitney U test. Ratios between resonances were defined as classifiers for new cases, and thresholds were selected with receiver operating characteristic (ROC) curves. The added value of spectroscopy was evaluated by 5 neuroradiologists and assessed with the Wilcoxon signed-rank test.
RESULTS: Differences between tumors and pseudotumors were found in myo-inositol (mIns); P < .01) at short TE, and N-acetylaspartate (NAA; P < .001), glutamine (Glx; P < .01), and choline (CHO; P < .05) at long TE. Classifiers suggested tumor when mIns/NAA ratio was more than 0.9 at short TE and also when CHO/NAA ratio was more than 1.9 at long TE. Classifier accuracy was tested in the test-set with the following results: short TE, 82% (23/28); long TE, 79% (22/28). The neuroradiologists' confidence rating of the test-cases on a 5-point scale (0-4) improved between 5% (from 2.86-3) and 27% (from 2.25-2.86) with spectroscopy (mean, 17%; P < .01).
CONCLUSIONS: The proposed ratios of mIns/NAA at short TE and CHO/NAA at long TE provide valuable information to discriminate between brain tumor and pseudotumor by improving neuroradiologists' accuracy and confidence.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19095788     DOI: 10.3174/ajnr.A1392

Source DB:  PubMed          Journal:  AJNR Am J Neuroradiol        ISSN: 0195-6108            Impact factor:   3.825


  20 in total

1.  Proton MR spectroscopy provides relevant prognostic information in high-grade astrocytomas.

Authors:  C Majós; J Bruna; M Julià-Sapé; M Cos; A Camins; M Gil; J J Acebes; C Aguilera; C Arús
Journal:  AJNR Am J Neuroradiol       Date:  2010-10-28       Impact factor: 3.825

Review 2.  MR imaging of neoplastic central nervous system lesions: review and recommendations for current practice.

Authors:  M Essig; N Anzalone; S E Combs; À Dörfler; S-K Lee; P Picozzi; A Rovira; M Weller; M Law
Journal:  AJNR Am J Neuroradiol       Date:  2011-10-20       Impact factor: 3.825

3.  Spatial Relationship of Glioma Volume Derived from 18F-FET PET and Volumetric MR Spectroscopy Imaging: A Hybrid PET/MRI Study.

Authors:  Jörg Mauler; Andrew A Maudsley; Karl-Josef Langen; Omid Nikoubashman; Gabriele Stoffels; Sulaiman Sheriff; Philipp Lohmann; Christian Filss; Norbert Galldiks; Elena Rota Kops; N Jon Shah
Journal:  J Nucl Med       Date:  2017-08-28       Impact factor: 10.057

4.  Cerebral metabolic changes in neurologically presymptomatic patients undergoing haemodialysis: in vivo proton MR spectroscopic findings.

Authors:  Ming-Lun Chiu; Chun-Wei Li; Jer-Ming Chang; I-Chan Chiang; Chih-Hung Ko; Hung-Yi Chuang; Reu-Sheng Sheu; Chen-Chang Lee; Tsyh-Jyi Hsieh
Journal:  Eur Radiol       Date:  2009-12-08       Impact factor: 5.315

5.  Magnetic resonance spectroscopic detection of lactate is predictive of a poor prognosis in patients with diffuse intrinsic pontine glioma.

Authors:  Fumiyuki Yamasaki; Kaoru Kurisu; Yoshinori Kajiwara; Yosuke Watanabe; Takeshi Takayasu; Yuji Akiyama; Taiichi Saito; Ryosuke Hanaya; Kazuhiko Sugiyama
Journal:  Neuro Oncol       Date:  2011-06-08       Impact factor: 12.300

6.  The INTERPRET Decision-Support System version 3.0 for evaluation of Magnetic Resonance Spectroscopy data from human brain tumours and other abnormal brain masses.

Authors:  Alexander Pérez-Ruiz; Margarida Julià-Sapé; Guillem Mercadal; Iván Olier; Carles Majós; Carles Arús
Journal:  BMC Bioinformatics       Date:  2010-11-29       Impact factor: 3.169

Review 7.  Imaging of brain tumors: MR spectroscopy and metabolic imaging.

Authors:  Alena Horská; Peter B Barker
Journal:  Neuroimaging Clin N Am       Date:  2010-08       Impact factor: 2.264

8.  Characterization of intracranial space-occupying lesions by ⁹⁹(m)Tc-Tetrofosmin SPECT.

Authors:  Andreas D Fotopoulos; Athanasios P Kyritsis; Spyridon Tsiouris; Jihad Al-Boucharali; Athanasios Papadopoulos; Spyridon Voulgaris; George A Alexiou
Journal:  J Neurooncol       Date:  2010-05-23       Impact factor: 4.130

9.  Lack of choline elevation on proton magnetic resonance spectroscopy in grade I-III gliomas.

Authors:  Sanjeev Chawla; Seung-Cheol Lee; Suyash Mohan; Sumei Wang; MacLean Nasrallah; Arastoo Vossough; Jaroslaw Krejza; Elias R Melhem; S Ali Nabavizadeh
Journal:  Neuroradiol J       Date:  2019-05-03

10.  Differential diagnosis of a vanishing brain space occupying lesion in a child.

Authors:  Sherifa A Hamed; Mohamad A Mekkawy; Hosam Abozaid
Journal:  World J Clin Cases       Date:  2015-11-16       Impact factor: 1.337

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.